Suggested remit: To appraise the clinical and cost effectiveness of amivantamab within its marketing authorisation for treating EGFR Exon 20 insertion-positive non-small-cell lung cancer.
 
Status In progress
Decision Selected
Process STA 2018
ID number 3836

Provisional Schedule

Committee meeting: 1 04 August 2022
Expected publication 12 October 2022

Project Team

Project lead Louise Jafferally

Email enquiries

Stakeholders

Companies sponsors Janssen-Cilag (amivantamab)
Others Department of Health and Social care
  NHS England
  Welsh Government
Patient carer groups EGFR Positive UK
  Roy Castle Lung Cancer Foundation
Professional groups Association of Cancer Physicians
  Cancer Research UK
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Radiologists
Associated guideline groups National Guideline Alliance
Associated public health groups None
Comparator companies MSD (pembrolizumab) (confidentiality agreement signed, participating)
  Accord Healthcare (docetaxel, carboplatin) (confidentiality agreement not signed, not participating)
  Boehringer Ingelheim (nintedanib) (confidentiality agreement not signed, not participating)
  Bristol-Myers Squibb (nivolumab) (confidentiality agreement not signed, not participating)
  Consilient Health (carboplatin) (confidentiality agreement not signed, not participating)
  Eli Lilly and Company (pemetrexed) (confidentiality agreement not signed, not participating)
  Hospira UK (docetaxel, carboplatin) (confidentiality agreement not signed, not participating)
  Roche products (atezolizumab) (confidentiality agreement not signed, not participating)
  Seacross Pharmaceuticals (docetaxel, pemetrexed) (confidentiality agreement not signed, not participating)
General commentators All Wales Therapeutic and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research

Timeline

Key events during the development of the guidance:

Date Update
04 June 2021 As you will be aware, the Department for Health and Social Care has asked NICE to conduct an appraisal of amivantamab for treating EGFR Exon 20 insertion-positive non-small-cell lung cancer after platinum-based chemotherapy. Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the deadline for submissions is now 9 February 2022. These timelines are based on a request from the company to reschedule in order to facilitate a suitably comprehensive and robust submission.
16 March 2021 Invitation to participate
13 January 2021 - 10 February 2021 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
01 September 2020 In progress. DHSC referral received

For further information on our processes and methods, please see our CHTE processes and methods manual